hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects-Reference-Cited by-同舟云学术

hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects

Published:2020-05-20 Issue:6 Volume:13 Page:1161-1169
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Lee Sang Won¹²,Choi Donghoon³,Heo MinKyu⁴,Shin Eui‐Cheol⁵⁶,Park Su‐Hyung⁵⁶,Kim So Jeong⁶,Oh Yeon‐Kyung⁴,Lee Byung Ha³,Yang Se Hwan³,Sung Young Chul⁴,Lee Howard¹⁷

Affiliation:

1. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine and Hospital Seoul Korea

2. Department of Clinical Pharmacology and Therapeutics Hanyang University Seoul Hospital Seoul Korea

3. NeoImmuneTech, Inc. Rockville Maryland USA

4. Genexine, Inc. Seongnam‐si Gyeonggi‐do Korea

5. Graduate School of Medical Science and Engineering Korea Advanced Institute of Science and Technology Daejeon Korea

6. Biomedical Science and Engineering Interdisciplinary Program Korea Advanced Institute of Science and Technology Daejeon Korea

7. Department of Transdisciplinary Studies Graduate School of Convergence Science and Technology Seoul National University Seoul Korea

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12800

Reference37 articles.

1. CD4 lymphopenia to identify end-of-life metastatic cancer patients

2. Survival in Patients With Severe Lymphopenia Following Treatment With Radiation and Chemotherapy for Newly Diagnosed Solid Tumors

3. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas

4. Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma

5. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Activation of Cell-Intrinsic Signaling in CAR-T Cells via a Chimeric IL7R Domain;Cancer Research Communications;2024-09-01

2. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors;Journal for ImmunoTherapy of Cancer;2024-07

3. IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy;Cell Reports Medicine;2024-05

4. Validity conditions of approximations for a target-mediated drug disposition model: A novel first-order approximation and its comparison to other approximations;PLOS Computational Biology;2024-04-24

5. From lymphopenia to restoration: IL-7 immunotherapy for lymphocyte recovery in glioblastoma;Cancer Letters;2024-04